Viridian Therapeutics, Inc. (VRDN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Viridian Therapeutics, Inc. on September 21, 2023. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The Board of Directors increased its size from five to six members. Dr. Sarah Gheuens was appointed as a new Class I director, effective September 21, 2023. She will serve until the 2025 Annual Meeting of Stockholders and has been appointed to the Science and Technology Committee.
Management Commentary and Compensation
Dr. Gheuens brings significant experience from Agios Pharmaceuticals (Chief Medical Officer and Head of R&D) and Biogen Inc. (Executive Medical Director). Her compensation package includes:
- An annualized cash fee of $46,000 for director and committee service.
- An option to purchase 40,000 shares of common stock under the 2016 Equity Incentive Plan.
- The option exercise price is set at the closing stock price on the grant date.
- Vesting occurs in equal monthly installments over three years, contingent on continued service.
The Company intends to enter into a standard indemnification agreement with Dr. Gheuens. No other material risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 40,000 stock options awarded to Dr. Gheuens.
- Review the Company's latest 10-Q or 10-K for current cash runway and liquidity status, as this 8-K contains no financial data.
- Confirm the composition of the Science and Technology Committee following this appointment.